Deals
Tower Capital-Led Consortium Weighs Eu Yan Sang Stake Sale, Sources Say
- Consortium is working with financial advisers on possible deal
- A disposal could value Eu Yan Sang at about $800 million
This article is for subscribers only.
A Tower Capital Asia-led consortium is considering selling its consumer health-care company Eu Yan Sang International Ltd., according to people with knowledge of the matter.
The Singapore-based mid-market private equity firm, along with Temasek Holdings Pte’s unit Blanca Investments and members of the founding family, are working with financial advisers on the planned disposal of their majority stake in the traditional Chinese medicine company, the people said. A deal could value Eu Yan Sang International, which was taken private in 2016, at about $800 million, said the people.